Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 24-week, Open-label, Randomized, 2-arm Parallel Group, Multinational, Multi-center Clinical Trial to Compare the Efficacy and Safety of Lixisenatide Injected Prior to the Main Meal of the Day Versus Lixisenatide Injected Prior to Breakfast in Type 2 Diabetic Patients Not Adequately Controlled on Metformin

NCT01517412 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT01517412
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01517412 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 24-week, Open-label, Randomized, 2-arm Parallel Group, Multinational, Multi-center Clinical Trial to Compare the Efficacy and Safety of Lixisenatide Injected Prior to the Main Meal of the Day Versus Lixisenatide Injected Prior to Breakfast in Type 2 Diabetic Patients Not Adequately Controlled on Metformin
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Completed
Start date
February 29, 2012
Completion date
May 31, 2013
Enrollment
451 (actual)
Sites
82

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus